







































# Clinical Trials for Adults















## In Person Clinical Trials











 <b>CELL THERAPY</b>	<p><b><u>FORWARD STUDY</u></b>  <b>AGES 18-65</b>  <b>2 EPISODES OF SEVERE HYPOGLYCEMIA</b>  <b>T1D AT LEAST 5 YEARS</b>  <b>LOCATION: MA</b></p>	
 <b>DEVICE</b>	<p><b><u>STRIVE STUDY</u></b>  <b>AGES 2-70</b>  <b>T1D AT LEAST 3 MONTHS (2-6) OR 1 YEAR (7-70)</b>  <b>CURRENT OMNIPOD 5 USER</b>  <b>LOCATION: MA</b></p>	
 <b>DEVICE</b>	<p><b><u>PRECISION II STUDY</u></b>  <b>AGES 18-75</b>  <b>T1D AT LEAST 3 MONTHS</b>  <b>LOCATION: MA</b></p>	
 <b>DEVICE</b>	<p><b><u>TANGO</u></b>  <b>PARTICIPANTS OVER 65</b>  <b>MDI OR PUMP</b>  <b>LOCATION: MA</b></p>	
 <b>OBSERVATIONAL</b>	<p><b><u>JOSLIN HEART AND KIDNEY</u></b>  <b>AGES 25-65    DIAGNOSED BEFORE 41</b>  <b>NORMAL/MODERATELY DECREASED</b>  <b>KIDNEY FUNCTION</b>  <b>LOCATION: MA</b></p>	



 OBSERVATIONAL	<b><u>PROMISE</u></b> PREGNANT WOMEN/BIOLOGICAL FATHERS OF OFFSPRING W/ 1ST DEGREE T1D RELATIVE LOCATION: MA	
 DRUG	<b><u>EFFECTS OF KETOSIS ON BRAIN FUNCTION</u></b> AGES 18-40 T1D AT LEAST 1 YEAR WITH A1C 6.5-9% USE OF CGM AND INSULIN PUMP LOCATION: MA	
 OBSERVATIONAL	<b><u>BONE HEALTH IN T1D YOUTH</u></b> AGES 6-20 WITH T1D AND WITHOUT T1D EARN UP TO \$300 LOCATION: MA	
 DEVICE	<b><u>EVERSENSE</u></b> PARTICIPANTS OVER 18 NOT CURRENTLY USING CGM LOCATION: VT	
 OBSERVATIONAL	<b><u>IMMUNE FUNCTION</u></b> ALL AGES T1DS AND/OR FAMILY MEMBERS OF T1DS EARN \$20 LOCAL LAB	
 BEHAVIORAL	<b><u>VERY LOW CARB DIET STUDY</u></b> AGES 18-40 T1D AT LEAST 1 YEAR WITH A1C 6.5-9% LOCATION: MA	
 BEHAVIORAL	<b><u>iACT FOR EATING DISORDERS</u></b> AGES 16-45 LIVING W/ EATING DISORDER LOCATION: RI	

 DRUG	<b><u>SUGARNSALT</u></b> AGES 18-75 T1D AT LEAST 8 YEARS eGFR between 20-60 and urine ACR of 200+. LOCATION: MA	
 DEVICE	<b><u>DIABETES STUDY IN PREGNANCY</u></b> PREGNANT WITH T1D LOCATION: MA	
 DEVICE	<b><u>AGE SENSOR VALIDATION</u></b> AGES 18+ WITH AND WITHOUT T1D EARN \$300 LOCATION: MA	
 SURVEY	<b><u>SPOTLIGHT AQ</u></b> AGES 16 - 25 BOSTON CHILDREN'S PATIENTS LOCATION: MA	
 DEVICE	<b><u>CIAO</u></b> AGES 18-35 or 65+ MULTIPLE DAILY INJECTIONS LOCATION: MA	

Virtual Clinical Trials		
 PREVENTION	<b><u>TRIALNET</u></b> DIRECT RELATIVES OF T1DS AGES 2-45 UNDER 18 CAN RESCREEN EVERY 2 YEARS VIRTUAL OR TRIALNET CENTER	
 SURVEY	<b><u>BC CONNELL SCHOOL OF NURSING</u></b> <b><u>COST OF T1D</u></b> AGES 18-30 ENGLISH SPEAKING EARN \$50 VIRTUAL	









 SURVEY	<b><u>DIABETES STIGMA</u></b> AGES 18+ T1D FOR AT LEAST 1 YEAR VIRTUAL	
 BEHAVIORAL	<b><u>DIGITAL STORYTELLING FOR TEENS</u></b> AGES 13-21 T1D FOR AT LEAST 1 YEAR VIRTUAL	
 BEHAVIORAL	<b><u>FAM STUDY</u></b> AGES 18-65 T1D FOR AT LEAST 1 YEAR A1C 7.5% - 14% VIRTUAL	
 BEHAVIORAL	<b><u>T1DAL</u></b> AGES 13-18 T1D AT LEAST 6 MONTHS EARN UP TO \$125 VIRTUAL	
 SURVEY	<b><u>T1D EXCHANGE REGISTRY</u></b> INDIVIDUALS WITH T1D AND/OR THEIR CAREGIVERS VIRTUAL	
 BEHAVIORAL	<b><u>TELE-MED COGNITIVE BEHAVIOR THERAPY</u></b> AGES 18-35 T1D AT LEAST 6 MONTHS WITH ANXIETY OR DEPRESSION VIRTUAL	
 BEHAVIORAL	<b><u>CGM SHARING IN OLDER ADULTS</u></b> AGES 60+ A1C 7.5-11% VIRTUAL	

 SURVEY	<b><u>TIME IN TIGHT RANGE</u></b> AGES 18+  VIRTUAL	
 BEHAVIORAL	<b><u>T1D BODY ACCEPTANCE PROJECT</u></b> FEMALES AGES 15-30 W/ BODY IMAGE CONCERNS AND/OR DISORGANIZED EATING EARN \$110  VIRTUAL/MA	
 DEVICE	<b><u>EXTENDED BOLUS CLOSED LOOP</u></b> AGES 13-18 T1D AT LEAST 1 YEAR USING CONTROL IQ  VIRTUAL	
 BEHAVIORAL	<b><u>TRANSDISCIPLINARY CARE FOR TRANSITION</u></b> AGES 17-25 APPROACHING PEDIATRIC DISCHARGE - EARN \$180  VIRTUAL	
 BEHAVIORAL	<b><u>ReDUCE</u></b> AGES 18-64 T1D AT LEAST 6 MONTHS A1C>7.5%  VIRTUAL	

Early Stage T1D Trial		
 OBSERVATIONAL	<b><u>PREDICT</u></b> AGES 12-30 AT LEAST 1 T1D ANTIBODY - EARN \$1500  LOCATION: CT	



# Newly Diagnosed Clinical Trials

 <b>DRUG</b>	<p><b><u>JAKPOT-T1D</u></b>  <b>AGES 12-35</b>  <b>T1D LESS THAN 100 DAYS, A1C &lt;10%</b>  <b>LOCATION: MA</b></p>	
 <b>DRUG</b>	<p><b><u>T1D RELAY</u></b>  <b>AGES 8-45</b>  <b>T1D LESS THAN 100 DAYS</b>  <b>LOCATION: MA</b></p>	
 <b>DRUG</b>	<p><b><u>DIAGNODE-3</u></b>  <b>AGES 12-28</b>  <b>WITHIN 6 MONTHS OF DIAGNOSIS</b>  <b>LOCATION: MA</b></p>	
 <b>DRUG</b>	<p><b><u>FABULINUS</u></b>  <b>AGES 12-35</b>  <b>T1D LESS THAN 90 DAYS W/ 1 ANTIBODY</b>  <b>LOCATION: MA</b></p>	

## Trial Tool and CTEV Contact Info

**Clinical Trials Connection Tool**  
**Match to a Clinical Trial in 60 Seconds**



**Breakthrough T1D Greater New England**  
**Clinical Trial Education Volunteers**  
**AmandaJGilchrist@gmail.com and Kristin.Neff@gmail.com**